insights_auto
Miks on 688235 tõusnud? 4,06%?
Uurige põhjalikumaltchevron_right
688235:SHA
BeOne Medicines AG
255,98Â CNÂ¥
arrow_upward
+4,06%(+9,99) 1 p
16. okt, 15:00:00 GMT +8 · CNY
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse 688235 põhistatistika genereerimine…
Ava
253,20Â CNÂ¥
Kõrge
268,18Â CNÂ¥
Madal
252,09Â CNÂ¥
Turu kapit.
290,70Â mld
Keskm. maht
2,81Â mln
Maht
5,69Â mln
Hinna ja tulu suhe
91,43
52 näd kõrgeim
319,24Â CNÂ¥
52 näd madalaim
205,51Â CNÂ¥
Aktsiatulu
2,80Â CNÂ¥
Töötajate arv
12Â tuh
Ava
253,20Â CNÂ¥
Kõrge
268,18Â CNÂ¥
Madal
252,09Â CNÂ¥
Turu kapit.
290,70Â mld
Keskm. maht
2,81Â mln
Maht
5,69Â mln
Hinna ja tulu suhe
91,43
52 näd kõrgeim
319,24Â CNÂ¥
52 näd madalaim
205,51Â CNÂ¥
Aktsiatulu
2,80Â CNÂ¥
Töötajate arv
12Â tuh
Uudised
Veebiallikatest ja uudistepartneritelt
Simply Wall Street
·
6 tunni eest
Is BeOne Medicines (ONC) Undervalued As Earnings Estimates Jump?
Profiil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Teave üksuse BeOne Medicines AG kohta
TegevjuhtJohn Vincent Oyler | John Vincent Oyler
Töötajad12 tuh
Asutatud28. okt 2010
Peakontorid-
Sektor-
Veebisaitbeonemedicines.com